Pneumococcal infections - Pipeline Insight, 2026

DelveInsight's, "Pneumococcal infections - Pipeline Insight, 2026" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Pneumococcal infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Pneumococcal infections: Understanding

Pneumococcal infections: Overview

Pneumococcal infections, caused by Streptococcus pneumoniae, continue to pose a significant global health burden, especially among children, the elderly, and immunocompromised individuals. The bacterium often resides in the nasopharynx and can lead to conditions ranging from mild illnesses such as otitis media to severe invasive diseases like pneumonia, meningitis, and sepsis. Transmission primarily occurs through respiratory droplets, with higher susceptibility linked to age, underlying diseases, and co-infections. Although pneumococcal conjugate vaccines have markedly reduced disease incidence and provided herd immunity, evolving serotypes necessitate ongoing vaccine improvements and surveillance.

Clinical manifestations vary depending on the site of infection, reflecting the broad disease spectrum of pneumococcal infections. Pneumonia typically presents with fever, chills, chest pain, productive cough, and breathing difficulty, while meningitis may cause headache, neck stiffness, vomiting, seizures, and altered mental status. Systemic infections like bacteremia or sepsis can result in fever, weakness, and organ dysfunction, whereas localized infections such as sinusitis and otitis media lead to ear pain, nasal discharge, and facial discomfort. Severe complications, including empyema, lung abscess, or pericarditis, may arise in advanced cases, highlighting the importance of timely diagnosis and appropriate treatment.

Pneumococcal infections are diagnosed through clinical assessment along with identification of Streptococcus pneumoniae in relevant body fluids. Culture from normally sterile sites remains the definitive standard, while sputum testing, urinary antigen assays, and PCR enhance detection, particularly after prior antibiotic use. Advanced techniques such as loop-mediated isothermal amplification (LAMP) and MALDI-TOF mass spectrometry enable faster and more precise identification, supported by imaging and routine laboratory tests. Prompt and accurate diagnosis is essential to initiate appropriate therapy and improve clinical outcomes.

Management of pneumococcal infections is determined by disease severity, site of infection, and local resistance trends, with early antibiotic therapy as the cornerstone. Mild cases are typically treated with agents such as amoxicillin, doxycycline, or macrolides, whereas severe or hospitalized patients often require combination regimens including B-lactams with macrolides or fluoroquinolones. Infections caused by resistant Streptococcus pneumoniae strains may necessitate the use of cefotaxime, ceftriaxone, or respiratory fluoroquinolones, with regimen modifications for meningitis and pediatric populations. Adjunctive supportive care, along with vaccination strategies, plays a crucial role in reducing complications and preventing recurrence.

"Pneumococcal infections- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pneumococcal infections pipeline landscape is provided which includes the disease overview and Pneumococcal infections treatment guidelines. The assessment part of the report embraces, in depth Pneumococcal infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pneumococcal infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Pneumococcal infections R&D. The therapies under development are focused on novel approaches to treat/improve Pneumococcal infections.

Pneumococcal infections Emerging Drugs Chapters

This segment of the Pneumococcal infections report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pneumococcal infections Emerging Drugs

VAX-24: Sutro Biopharma, Inc.

VAX-24 is a 24-valent pneumococcal conjugate vaccine developed by Vaxcyte, Inc. to prevent invasive infections caused by Streptococcus pneumoniae. It utilizes an advanced cell-free protein synthesis platform to enable precise conjugation of 24 pneumococcal polysaccharide serotypes. The vaccine is designed to provide broader serotype coverage along with enhanced immunogenicity compared to existing options. VAX-24 is currently undergoing Phase III clinical trials for the prevention of pneumococcal infections.

IVT PCV-25: Inventprise

IVT PCV-25 is a 25-valent pneumococcal conjugate vaccine being developed by Inventprise, Inc. for the prevention of infections caused by Streptococcus pneumoniae. It is designed to target 25 pneumococcal serotypes using advanced conjugation technology to enhance immune protection. The vaccine aims to provide broader serotype coverage and improved immunogenicity compared to existing pneumococcal vaccines. IVT PCV-25, is currently in development for both pediatric and adult populations globally and are both in Phase II clinical trial.

Pneumococcal infections: Therapeutic Assessment

This segment of the report provides insights about the different Pneumococcal infections drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Pneumococcal infections
• There are approx. 18+ key companies which are developing the therapies for Pneumococcal infections. The companies which have their Pneumococcal infections drug candidates in the most advanced stage, i.e. Phase III include, Sutro Biopharma, Inc.
• Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Pneumococcal infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pneumococcal infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Pneumococcal infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pneumococcal infections drugs.

Pneumococcal infections Report Insights

• Pneumococcal infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pneumococcal infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pneumococcal infections drugs?
• How many Pneumococcal infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pneumococcal infections?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pneumococcal infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pneumococcal infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sutro Biopharma, Inc.
• Inventprise
• LiteVax BV
• Merck
• GlaxoSmithKline
• CanSinoBIO
• Abera Bioscience AB
• GPN Vaccines
• Panacea Biotec
• Virometix AG

Key Products

• VAX-24
• IVT PCV-25
• PCV LITE
• V118C
• GSK5459248
• PCV24
• Ab-01.12
• Gamma-PN
• NuVac-23
• V-212